Human Antimicrobial Peptide LL-37 Induces MefE/Mel-Mediated Macrolide Resistance in Streptococcus pneumoniae
|
|
- Kenneth Gibson
- 5 years ago
- Views:
Transcription
1 Human Antimicrobial Peptide LL-37 Induces MefE/Mel-Mediated Macrolide Resistance in Streptococcus pneumoniae Dorothea Zahner, Emory University Xiaoliu Zhou, Emory University Scott Chancey, Emory University Jan Pohl, Emory University William M Shafer, Emory University David S Stephens, Emory University Journal Title: Antimicrobial Agents and Chemotherapy Volume: Volume 54, Number 8 Publisher: American Society for Microbiology , Pages Type of Work: Article Final Publisher PDF Publisher DOI: /AAC Permanent URL: Final published version: Copyright information: 2010, American Society for Microbiology Accessed March 18, :47 PM EDT
2 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2010, p Vol. 54, No /10/$12.00 doi: /aac Copyright 2010, American Society for Microbiology. All Rights Reserved. Human Antimicrobial Peptide LL-37 Induces MefE/Mel-Mediated Macrolide Resistance in Streptococcus pneumoniae Dorothea Zähner, 1,4 Xiaoliu Zhou, 1,4 Scott T. Chancey, 1,4 Jan Pohl, 3 William M. Shafer, 2,4 and David S. Stephens 1,2,4 * Division of Infectious Diseases, Department of Medicine, 1 and Department of Microbiology and Immunology, 2 Emory University School of Medicine, Atlanta, Georgia 30322; Biotechnology Core Facility Branch, Centers for Disease Control and Prevention, Atlanta, Georgia ; and Department of Veterans Affairs Medical Center (Atlanta), Decatur, Georgia Received 12 December 2009/Returned for modification 13 March 2010/Accepted 14 May 2010 Macrolide resistance is a major concern in the treatment of Streptococcus pneumoniae. Inducible macrolide resistance in this pneumococcus is mediated by the efflux pump MefE/Mel. We show here that the human antimicrobial peptide LL-37 induces the mefe promoter and confers resistance to erythromycin and LL-37. Such induction may impact the efficacy of host defenses and of macrolide-based treatment of pneumococcal disease. Macrolides are in widespread use and are recommended as the first line of treatment for community-acquired pneumonia (CAP), except in areas compromised by high rates of macrolide resistance (25). Macrolide resistance is therefore a major concern in the treatment of Streptococcus pneumoniae, a major causative agent of CAP, sinusitis, otitis media, and meningitis. In S. pneumoniae, macrolide resistance is conferred primarily by the methylase ErmB (MIC 64 g/ml) or the macrolide efflux pump Mef/Mel (1, 20, 30). Mef/Mel-mediated efflux has been shown to be specific for 14- and 15-membered macrolides (2, 32). Mef is encoded by two variants, either mefe or mefa, with mefe being more prevalent in the United States (2). MefE/Mel is encoded on the mobile genetic element mega (8) and has been shown to be inducible by 14- and 15-membered macrolides (1, 2, 32). MefE/Mel-mediated MICs for erythromycin range from 1 to 32 g/ml and increase by 4-fold upon macrolide induction, on average (37). The clinical implications of low-level macrolide resistance (1 to 8 g/ml) are controversial (3, 14, 17, 26). Recent studies provide evidence that infection with low-level macrolide-resistant pneumococci constitutes a risk factor for treatment failure (5, 4, 13, 22, 23). About 35% of all pneumococcal isolates from community-acquired respiratory tract infections in the Unites States are macrolide resistant, and Mef/Mel is present in more than 50% of the resistant isolates (15). Cationic antimicrobial peptides (CAMPs) are small cationic, amphiphilic peptides. The major mammalian CAMPs are cathelicidins and defensins, which are constitutively expressed in macrophages and neutrophils and inducibly produced by epithelial cells and at mucosal surfaces. They play an important role in host defense against bacterial infections and are a major component of the innate immune response (11, 19). Sublethal * Corresponding author. Mailing address: Department of Veterans Affairs Medical Center, Research 151, Room 5A188, 1670 Clairmont Road, Decatur, GA Phone: (404) Fax: (404) dstep01@emory.edu. Present address: Centers for Disease Control and Prevention, Chamblee, GA. Published ahead of print on 24 May concentrations of CAMPs are known to alter the levels of bacterial gene expression (9). In this respect, we determined that the sole human cathelicidin, LL-37, could alter mefe and mel expression and that this alters pneumococcal susceptibility to macrolides and LL-37. LL-37 induces the mefe promoter. In a screen for inducers of the MefE/Mel efflux pump, several cationic antimicrobial peptides were tested in a plate diffusion assay with a mefe promoter-lacz reporter strain. The reporter strain was constructed by introducing a 1.1-kb fragment containing the mefe promoter (PmefE) region of S. pneumoniae strain GA17457 (bp 1 to 1,178 based on the published, identical mega nucleotide sequence of strain GA3488; GenBank accession number AF [8]) as an XbaI/EcoRI fragment upstream of the lacz gene in vector ppp2 (10). The resulting plasmid was used to transform S. pneumoniae strain GA17457, leading to the integration of PmefE-lacZ in the bga locus in reporter strain XZ7042. GA17457 is a clinical isolate (serotype 19A), which has a mega element as its sole erythromycin resistance determinant. For plate diffusion assays, XZ7042 was streaked onto indicator plates (Todd-Hewitt [TH] medium supplemented with 1.5% agarose, 0.5% yeast extract, 300 U/ml catalase, and 0.004% 5-bromo-4-chloro-3-indolyl- -D-galactopyranoside [X- Gal]), and a test compound was applied to the center of the plates. After 36 h at 37 C with 5% CO 2, the plates were evaluated for a zone of growth inhibition and an adjacent zone of induction. Under inducing conditions, as shown for erythromycin (Fig. 1A), the zone of induction appears as a blue halo around the inhibition zone. We tested several CAMPs of different origins, including polymyxin B (bacterial, 750 g), cathepsin G-derived peptide (CG ; human, 75 g), protegrin 1 (porcine, 75 g), and tachyplesin 1 (horseshoe crab, 75 g), and a mixture of -defensins, containing the human neutrophil peptides HNP1-3 (25 g) and the cathelicidins LL-37 (human, 75 g) and CRAMP38 and CRAMP39 (both murine, 75 g each). CRAMP38 and CRAMP39 are two alternatively processed forms of the LL-37 mouse homolog CRAMP (7). All peptides were prepared synthetically, except for HNP1-3 (Hycult Bio- 3516
3 VOL. 54, 2010 LL-37-INDUCED MACROLIDE RESISTANCE IN S. PNEUMONIAE 3517 FIG. 1. Induction of PmefE-lacZ by CAMPs. Plate diffusion assay shown on X-Gal indicator plates with erythromycin (A; positive control, 10 g), acetic acid (B; negative control, 15 l), human cathelicidin LL-37 (C; 75 g), and mouse cathelicidins CRAMP38 (D; 75 g) and CRAMP39 (E; 75 g) tested against PmefE-lacZ reporter strain XZ7042. technology, Uden, Netherlands), and were dissolved in 0.01% acetic acid. Acetic acid did not inhibit growth or induce PmefElacZ in XZ7042 (Fig. 1B). All tested peptides showed zones of growth inhibition in XZ7042 (data not shown), but only LL-37, CRAMP38, and CRAMP39 induced PmefE-lacZ (Fig. 1C to E). These results demonstrated that LL-37 induced PmefElacZ and that this induction was specific for the cathelicidins. LL-37 induction of PmefE confers resistance to LL-37 and erythromycin. In order to learn if induction of PmefE by LL-37 has biological significance, we tested whether induction of PmefE-lacZ with LL-37 confers resistance to LL-37 or erythromycin using microdilution assays optimized for MIC determination of CAMPs (28). Cultures were grown to an optical density at 600 nm (OD 600 ) of 0.4, split, and grown with or without addition of subinhibitory concentrations of LL-37 or erythromycin for 1 h. The subinhibitory concentrations used (Table 1) did not appear to affect growth of the bacteria, as assessed by determination of the CFU, but were sufficiently high to induce PmefE-lacZ in the reporter strain (data not shown). A final concentration of bacteria/ml adjusted in 5-fold-diluted TH medium supplemented with 0.5% yeast extract was added to serial dilutions of LL-37 or erythromycin. After 1 h at 37 C, samples were plated on TSA II blood agar plates (BD), and after 16 h at 37 C with 5% CO 2, the MICs and the minimal bactericidal concentrations (MBCs) were determined. Wild-type strain GA17457 and the PmefE-lacZ reporter derivative XZ7042 showed high levels of resistance to LL-37 (Table 1), which were further increased upon growth in subinhibitory concentrations of LL-37 (Table 1). Concomitantly, the MIC for erythromycin increased by 2- to 16-fold. Growth in the presence of erythromycin caused an increase in LL-37 resistance, as well as a 4-fold increase in erythromycin resistance. Taken together, independent of the nature of the inducer, induction increased resistance toward both compounds. In regard to the MBCs, LL-37 induction of resistance was less pronounced than that with erythromycin, consistent with the weaker induction observed with LL-37 in the plate diffusion assay (Fig. 1A and C). To determine whether the increased resistance to LL-37 and erythromycin relied on the mega element, two mega deletion mutants were constructed. By allelic replacement, the 5.5-kb mega region (bp 1 to 5,532; GenBank accession number AF274302) was replaced in GA17457 and XZ7042 with the spectinomycin resistance cassette (containing the aad9 gene) from puc-spc (12). The resulting mutants XZ8006 and XZ8004, respectively, were less resistant to LL-37 than their parental strains and were susceptible to erythromycin, confirming that mega was required for resistance (Table 1). In addition, growth in the presence of subinhibitory concentrations of LL-37 did not induce increased resistance to LL-37 or erythromycin (Table 1); hence, inducible resistance in the wild-type strains required the mega element. We analyzed whether pneumococcal resistance to LL-37 required the MefE/Mel efflux pump encoded on mega. A mefe-mel deletion mutant, XZ8009, was constructed by replacing the region containing the mefe and mel genes (from bp 83 in mefe to bp 3,858 in mel) with the kanamycin resistance cassette (containing the aph3 gene) of psf191 (33) in GA XZ8009 showed the same levels of resistance to LL-37 as the mega-deletion mutants under all tested conditions (Table 1), demonstrating that the Strain TABLE 1. MICs and MBCs of wild-type, mega, and mefe-mel mutant strains for LL-37 and erythromycin e Genotype Uninduced LL-37 Induced with LL-37 b MIC (MBC) a Induced with Em c Uninduced Em Induced with LL-37 b Induced with Em c GA17457 Wild type, parent 500 (1,000) 2,000 ( 2,000) 2,000 ( 2,000) 2 (16) 8 (32) 8 ( 64) 12 XZ8006 mega::aad9 125 (250) 125 (250) N/A 0.5 (4) 0.5 (4) N/A XZ8009 mefe-mel::aph3 125 (250) 64 (250) N/A 0.5 (4) (2) N/A XZ7042 bgaa::pmefe-lacz 500 (1,000) 2,000 ( 2,000) 2,000 ( 2,000) 1 (8) 16 (32) 4 ( 64) 12 XZ8004 mega::aad9 bgaa::pmefe-lacz 250 (500) 125 (250) N/A 0.25 (4) 0.5 (4) N/A a MICs and MBCs ( g/ml) determined by microdilution assays adapted to CAMPs (28). Em, erythromycin; N/A, not applicable because the strain was erythromycin sensitive. b Subinhibitory concentrations used for induction: GA17457 and XZ7042, 200 g/ml; XZ8006 and XZ8009, 50 g; and XZ8004, 100 g. c Subinhibitory concentration used for induction: 1 g/ml. d Etest was performed according to the manufacturer s instructions (AB Biodisk, Solna, Sweden). e Shown are the results obtained from one representative experiment, and at least three independent experiments were performed. Etest value d
4 3518 ZÄHNER ET AL. ANTIMICROB. AGENTS CHEMOTHER. MefE/Mel efflux pump mediated the resistance to LL-37 and erythromycin. Induction of MefE/Mel-mediated resistance by LL-37 was an unexpected finding, especially after a rather narrow spectrum of 14- and 15-membered macrolides had been described as inducers/substrates of this efflux pump (32, 37). The potential clinical implications of this finding are 2-fold, as follows: (i) failure of macrolide-based treatment of mega-containing strains due to host-mediated induction of MefE/Mel by LL-37, resulting in a higher level of resistance, and (ii) underestimation of macrolide resistance of mega-containing strains, based on in vitro MICs determined under noninducing conditions. To assess the in vivo induction of MefE/Mel by LL-37, further studies are required to determine whether local concentrations of LL-37 in the host are sufficiently high to cause induction. Serum concentrations of LL-37 are reported to be in the g/ml range and can increase dramatically during acute inflammation; however, the local concentrations may vary greatly (27, 29). Daneman et al. have described that the risk for macrolide treatment failures increased with MICs of 1 g/ml but did not increase further with higher MICs (4). Their finding would be consistent with low-level in vitro MICs, as observed for mega-containing isolates, that increase upon in vivo induction of a resistance determinant, resulting in MICs that exceed the threshold established by existing guidelines (MICs 16 g/ml) (25) beyond which macrolides should no longer be used. Taken together, induction of MefE/Mel by LL-37 provides an intriguing, possible explanation for the observed macrolide treatment failures in disease caused by low-level-resistant pneumococci (3, 5, 6, 13, 14, 16, 22, 23). S. pneumoniae is naturally resistant to high levels of CAMPs, which has been attributed to mechanisms altering the surface charge, thereby decreasing CAMP affinity, and to several other factors that await further characterization (18, 21, 24, 31, 35, 36). Recently, Majchrzykiewicz et al. (24) have shown that incubation with LL-37 altered expression of 10% of the genome in S. pneumoniae, including the genes of known and putative regulatory proteins, suggesting the possibility of an indirect induction of Mef/Mel by LL-37. Our data suggest that the MefE/Mel efflux pump can further contribute to cathelicidin resistance and may thereby contribute to increased survival in the human host. Due to the limitations of our in vitro assay system, which required high concentrations of LL-37 at or beyond the soluble concentration of LL-37 ( 2,000 g/ml), this important observation needs to be further evaluated for biological significance with in vivo experiments. Actual effluxmediated cathelicidin resistance has been demonstrated for the MtrCDE efflux pump of Neisseria spp. (28, 34). This additional function of MefE/Mel could account for an increasing number of pneumococcal isolates that contain both macrolide resistance determinants ErmB and MefE/Mel (15). Due to the high-resistance levels associated with ErmB, MefE/Mel does not contribute to macrolide resistance, but it may help protect MefE/Mel-containing strains from antimicrobial host defenses. This work was supported by funding from NIH grants AI (to D.S.S.) and AI (to W.M.S.) and a VA Merit Award (to D.S.S.). W.M.S. was supported in part by a Senior Research Career Scientist Award from VA Medical Research Service. REFERENCES 1. Ambrose, K. D., R. Nisbet, and D. S. Stephens Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob. Agents Chemother. 49: Daly, M. M., S. Doktor, R. Flamm, and D. Shortridge Characterization and prevalence of MefA, MefE, and the associated msr(d) gene in Streptococcus pneumoniae clinical isolates. J. Clin. Microbiol. 42: Daneman, N., D. E. Low, A. McGeer, K. A. Green, and D. N. Fisman At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin. Infect. Dis. 46: Daneman, N., A. McGeer, K. Green, and D. E. Low Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin. Infect. Dis. 43: File, T. M., Jr Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin. Microbiol. Infect. 12(Suppl. 3): Fogarty, C., R. Goldschmidt, and K. Bush Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin. Infect. Dis. 31: Gallo, R. L., K. J. Kim, M. Bernfield, C. A. Kozak, M. Zanetti, L. Merluzzi, and R. Gennaro Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272: Gay, K., and D. S. Stephens Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J. Infect. Dis. 184: Gryllos, I., H. J. Tran-Winkler, M. F. Cheng, H. Chung, R. Bolcome III, W. Lu, R. I. Lehrer, and M. R. Wessels Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proc. Natl. Acad. Sci. U. S. A. 105: Halfmann, A., R. Hakenbeck, and R. Bruckner A new integrative reporter plasmid for Streptococcus pneumoniae. FEMS Microbiol. Lett. 268: Hancock, R. E Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1: Husmann, L. K., D. L. Yung, S. K. Hollingshead, and J. R. Scott Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect. Immun. 65: Iannini, P. B., J. A. Paladino, B. Lavin, M. E. Singer, and J. J. Schentag A case series of macrolide treatment failures in community acquired pneumonia. J. Chemother. 19: Jacobs, M. R In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin. Infect. Dis. 35: Jenkins, S. G., and D. J. Farrell Increase in pneumococcus macrolide resistance, United States. Emerg. Infect. Dis. 15: Kelley, M. A., D. J. Weber, P. Gilligan, and M. S. Cohen Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31: Klugman, K. P., and J. R. Lonks Hidden epidemic of macrolideresistant pneumococci. Emerg. Infect. Dis. 11: Kovacs, M., A. Halfmann, I. Fedtke, M. Heintz, A. Peschel, W. Vollmer, R. Hakenbeck, and R. Bruckner A functional dlt operon, encoding proteins required for incorporation of D-alanine in teichoic acids in grampositive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae. J. Bacteriol. 188: Lai, Y., and R. L. Gallo AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30: Leclercq, R., and P. Courvalin Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: Lee, H. Y., A. Andalibi, P. Webster, S. K. Moon, K. Teufert, S. H. Kang, J. D. Li, M. Nagura, T. Ganz, and D. J. Lim Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect. Dis. 4: Lonks, J. R What is the clinical impact of macrolide resistance? Curr. Infect. Dis. Rep. 6: Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. Ochoa de Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35: Majchrzykiewicz, J. A., O. P. Kuipers, and J. J. Bijlsma Generic and specific adaptative response of Streptococcus pneumoniae to challenge with three distinct antimicrobial peptides: bacitracin, LL-37 and nisin. Antimicrob. Agents Chemother. 54: Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney Infectious Diseases Society of America/
5 VOL. 54, 2010 LL-37-INDUCED MACROLIDE RESISTANCE IN S. PNEUMONIAE 3519 American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27 S Nuermberger, E., and W. R. Bishai The clinical significance of macrolide-resistant Streptococcus pneumoniae: it s all relative. Clin. Infect. Dis. 38: Ong, P. Y., T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R. L. Gallo, and D. Y. Leung Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347: Shafer, W. M., X. Qu, A. J. Waring, and R. I. Lehrer Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc. Natl. Acad. Sci. U. S. A. 95: Sørensen, O., J. B. Cowland, J. Askaa, and N. Borregaard An ELISA for hcap-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206: Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40: Swiatlo, E., F. R. Champlin, S. C. Holman, W. W. Wilson, and J. M. Watt Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect. Immun. 70: Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe mefe is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41: Tao, L., D. J. LeBlanc, and J. J. Ferretti Novel streptococcal-integration shuttle vectors for gene cloning and inactivation. Gene 120: Tzeng, Y. L., K. D. Ambrose, S. Zughaier, X. Zhou, Y. K. Miller, W. M. Shafer, and D. S. Stephens Cationic antimicrobial peptide resistance in Neisseria meningitidis. J. Bacteriol. 187: Vollmer, W., and A. Tomasz The pgda gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae. J. Biol. Chem. 275: Wartha, F., K. Beiter, B. Albiger, J. Fernebro, A. Zychlinsky, S. Normark, and B. Henriques-Normark Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell. Microbiol. 9: Wierzbowski, A. K., D. Boyd, M. Mulvey, D. J. Hoban, and G. G. Zhanel Expression of the mef(e) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. Antimicrob. Agents Chemother. 49:
Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin
2009 21 1) 1, 2) 1, 2) 1) 1) 2) 1) 1) 1) 1) 1) 1, 2) 1) 2) 20 2 29 21 1 14 Streptococcus pneumoniae 356 moxifloxacin (MFLX), garenoxacin (GRNX) sitafloxacin (STFX), DX619 S. pneumoniae S. pneumoniae 60
More informationDISTRIBUTION OF MACROLIDE-RESISTANT GENES AMONG ISOLATES OF MACROLIDE- RESISTANT STREPTOCOCCUS PYOGENES AND STREPTOCOCCUS PNEUMONIAE IN SERBIA
Arch. Biol. Sci., Belgrade, 66 (1), 93-98, 2014 DOI:10.2298/ABS1401093G DISTRIBUTION OF MACROLIDE-RESISTANT GENES AMONG ISOLATES OF MACROLIDE- RESISTANT STREPTOCOCCUS PYOGENES AND STREPTOCOCCUS PNEUMONIAE
More informationReceived 20 November 2013; returned 19 March 2014; revised 10 April 2014; accepted 19 May 2014
J Antimicrob Chemother 2014; 69: 2835 2840 doi:10.1093/jac/dku207 Advance Access publication 11 June 2014 Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract
More informationDissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(b) and mef(a) in South Korea
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2003, p. 5787 5791 Vol. 41, No. 12 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.12.5787 5791.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationEnvironmental survival of Neisseria meningitidis
Environmental survival of Neisseria meningitidis Yih-Ling Tzeng, Emory University L.E. Martin, Emory University David Stephens, Emory University Journal Title: Epidemiology and Infection Volume: Volume
More informationIncreasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2008, p. 1190 1194 Vol. 52, No. 3 0066-4804/08/$08.00 0 doi:10.1128/aac.01260-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Increasing
More informationMacrolide-resistant phenotypes of invasive Streptococcus pneumoniae isolates in Serbia
Arch. Biol. Sci., Belgrade, 64 (4), 1377-1382, 2012 DOI:10.2298/ABS1204377G Macrolide-resistant phenotypes of invasive Streptococcus pneumoniae isolates in Serbia Ina GajiĆ, NataŠa Opavski, Vera MIJAČ
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationIn vitro and Intracellular Activities of Peptide Deformylase. Inhibitor GSK against Legionella pneumophila Isolates
AAC Accepts, published online ahead of print on 27 October 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04006-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationMacrolide-Resistant Pneumococcal Endocarditis and Epidural Abscess that Develop during Erythromycin Therapy
MAJOR ARTICLE Macrolide-Resistant Pneumococcal Endocarditis and Epidural Abscess that Develop during Erythromycin Therapy Jay C. Butler, 1 Jeffrey L. Lennox, 2,3 Linda K. McDougal, 4 Joyce A. Sutcliffe,
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationMacrolides, Clindamycin & Ketolides Polymyxins
Macrolides, Clindamycin & Ketolides Polymyxins Kwan Soo Ko Macrolides - Erythromycin - Azithromycin - Clarithromycin Lincosamides - Lincomycin - Clindamycin Unrelated chemically But, many similar biological
More informationIn vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae
AAC Accepted Manuscript Posted Online 26 January 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.04127-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 In vitro assessment
More informationMolecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae
medicaldaily.com http://en.vircell.com/diseases ppcorn.com Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae Robert Nicholas University of North Carolina at Chapel Hill cdc.gov Timeline
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00869.x Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy I. Serrano, M. Ramirez, the Portuguese Surveillance
More informationEpidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell
LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory
More informationMacrolides & Ketolides. Objectives. Protein Synthesis
Macrolides & Ketolides Elizabeth D. Hermsen, Pharm.D. Infectious Diseases Research Fellow University of Minnesota College of Pharmacy bjectives Participant should be able to explain macrolide/ketolide
More informationAspirin antagonism in isonizaid treatment of tuberculosis in mice ACCEPTED. Department of Molecular Microbiology & Immunology, Bloomberg School of
AAC Accepts, published online ahead of print on 4 December 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01145-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEffect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni
Effect of efflux pump inhibitors on antimicrobial resistance and in vivo colonization of Campylobacter jejuni J. Lin & M. Ensminger Department of Animal Science, The University of Tennessee, Knoxville,
More informationACCEPTED ANTIPNEUMOCOCCAL ACTIVITY OF LBM415 COMPARED TO OTHER AGENTS. KLAUDIA KOSOWSKA-SHICK KIM L. CREDITO GLENN A. PANKUCH BONIFACIO DEWASSE
AAC Accepts, published online ahead of print on 20 November 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01150-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMulti-drug Resistant Serotype 19A Pneumococci in Toronto
TML Lab Rounds January 17, 2008 Multi-drug Resistant Serotype 19A Pneumococci in Toronto The Role of the Microbiology Lab Susan M. Poutanen, MD, MPH, FRCPC Microbiologist/ID Consultant, TML/MSH Assistant
More informationABIMMUNE Repurposing disused antibiotics with immune modulators as antimicrobial strategy for respiratory tract infections
ABIMMUNE Repurposing disused antibiotics with immune modulators as antimicrobial strategy for respiratory tract infections Jean-Claude Sirard Christophe Carnoy Fiordiligie Casilag Delphine Cayet The partners
More informationTesting for Induction of Clindamycin Resistance in Erythromycin-Resistant Isolates of Staphylococcus aureus
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2005, p. 1716 1721 Vol. 43, No. 4 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.4.1716 1721.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationPATHOGENICITY OF MICROORGANISMS
PATHOGENICITY OF MICROORGANISMS Some microorganisms are : 1- Harmless microorganism, as normal flora 2- Harmfull microorganism, as pathogenic. A pathogenic microorganism is defined as one that causes or
More informationResistance to new anti-grampositive. Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France
Resistance to new anti-grampositive agents Roland Leclercq, Microbiology, CHU Cote de Nacre, Caen, France Recently available antimicrobials against MDR Gram-positive infections Cyclic lipopeptide: daptomycin
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationDepartment of Infection, GKT School of Medicine, St Thomas Hospital, London, UK
ORIGINAL ARTICLE Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin A. King, T. Bathgate and I. Phillips Department
More informationPHENOTYPES AND GENOTYPES OF MACROLIDE-RESISTANT STREPTOCOCCUS PNEUMONIAE IN SERBIA
Arch. Biol. Sci., Belgrade, 66 (1), 99-105, 2014 DOI:10.2298/ABS1401099H PHENOTYPES AND GENOTYPES OF MACROLIDE-RESISTANT STREPTOCOCCUS PNEUMONIAE IN SERBIA MIRJANA HADNAĐEV 1, INA GAJIĆ 2, VERA MIJAC 2,
More informationSteven D. Brown* and Maria M. Traczewski. The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2010, p. 2063 2069 Vol. 54, No. 5 0066-4804/10/$12.00 doi:10.1128/aac.01569-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Comparative
More informationProtein Synthesis Inhibitors. Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8
Protein Synthesis Inhibitors Ass Prof. Dr. Naza M. Ali 15 Nov 2018 Lec 8 These drugs selectively inhibit bacterial protein synthesis. The selectivity is due to the differences between bacterial and human
More informationbiological mechanisms Streptococcus pneumoniae virulence factors Mycobacterium tuberculosis pathogenesis Bacillus anthracis vaccine development
http://www.microbio.uab.edu/ Bacteriology at UAB Streptococcus pneumoniae Mycobacterium tuberculosis Bacillus anthracis Mycoplasma biological mechanisms virulence factors pathogenesis vaccine development
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationSTREPTOCOCCUS ANGINOSUS
STREPTOCOCCUS ANGINOSUS Streptococcus anginosus Group Bacteria: No longer a Case of Mistaken Identity Ralph K. Funckerstorff et al. Article Review by Andrea Prinzi INTRODUCTION In 1906, two scientists
More informationStreptococcus pneumonia
Streptococcus pneumonia The pneumococci (S. pneumoniae) are gram-positive diplococci. Often lancet shaped or arranged in chains, possessing a capsule of polysaccharide that permits typing with specific
More informationADI_Res_Bull_2013_Pneumococcal_Vaccine_Tests
ADI_Res_Bull_2013_Pneumococcal_Vaccine_Tests Most non-vaccinated humans and some animals have a natural exposure to non-virulent strains Streptococcus pneumonia, and therefore contain high levels of antibodies
More informationINTRODUCTION TO UPPER RESPIRATORY TRACT DISEASES
Upper Respiratory Tract Infections Return to Syllabus INTRODUCTION TO UPPER RESPIRATORY TRACT DISEASES General Goal: To know the major mechanisms of defense in the URT, the major mechanisms invaders use
More informationStreptococci facultative anaerobe
THE GENUS STREPTOCOCCUS The genus Streptococcus obtains Gram-positive cocci, nonmotile, nonsporeforming, arranged mostly in chains or in pairs. Most species are facultative anaerobes. Some of streptococci
More informationMolecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010
Zhou et al. BMC Microbiology 2012, 12:228 RESEARCH ARTICLE Open Access Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing,
More informationAAC Accepts, published online ahead of print on 19 March 2007 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 19 March 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01000-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEmergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes
Emergence et impact clinique de la résistance aux antibiotiques chez Chlamydia trachomatis, Neisseria gonorrhoeae, les mycoplasmes Cécile Bébéar French National Center for bacterial STIs Bordeaux University
More informationRole of Human Neutrophil Peptide 1 as a Possible Adjunct to Antituberculosis Chemotherapy
MAJOR ARTICLE Role of Human Neutrophil Peptide 1 as a Possible Adjunct to Antituberculosis Chemotherapy Anjana Kalita, Indu Verma, and G. K. Khuller Department of Biochemistry, Postgraduate Institute of
More informationRetapamulin Inhibition of Translation and ACCEPTED. 50S Ribosomal Subunit Formation in. Staphylococcus aureus Cells
AAC Accepts, published online ahead of print on 11 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00475-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationResistance among Streptococcus pneumoniae Clinical Isolates by Use of the E Test
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1994, p. 159-163 0095-1137/94/$04.00+0 Copyright 1994, American Society for Microbiology Vol. 32, No. 1 Detection of Penicillin and Extended-Spectrum Cephalosporin
More informationIntroduction. Journal of Antimicrobial Chemotherapy (2008) 62, Suppl. 2, ii87 ii95 doi: /jac/dkn355
Journal of Antimicrobial Chemotherapy (2008) 62, Suppl. 2, ii87 ii95 doi:10.1093/jac/dkn355 Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationGAS surveillance. emm12 emm28 emm89 GAS GAS. A GAS Streptococcus pyogenes GAS GAS PSAGN GAS GAS. emm. Vol. 26 No GAS surveillance study group
014 Vol. 6No. 11 A 1 1 GAS surveillance study group A GAS GAS surveillance study group01 GAS 44 PCR 60 GAS emm emm8emm8 GAS emm GAS A GASStreptococcus pyogenes GAS 1 6 1 GAS 1, GAS GAS GAS PSAGN GAS Key
More informationTELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT
Volume 19, Issue 12 September 2004 TELITHROMYCIN (KETEK ) A NEW ANTIMICROBIAL AGENT Christopher Cha, Pharm.D. Candidate Introduction Infections that invade the lower respiratory tract, such as community-acquired
More informationtelithromycin oral streptococci 140 telithromycin TEL azithromycin AZM clarithromycin CAM roxithromycin RXM levofloxacin LVFX ampicillin ABPC
telithromycin 3 0 3 0 oral streptococci 0 telithromycintelazithromycin AZMclarithromycinCAMroxithromycinRXMlevofloxacinLVFXampicillinABPC erythromycinem TEL EM erm mef 5 Streptococcus mitis MIC90 ml TEL
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationThesis for doctoral degree (Ph.D.) 2007 Molecular epidemiology of pneumococcal carriage and invasive disease Karin Sjöström.
Thesis for doctoral degree (Ph.D.) 2007 Thesis for doctoral degree (Ph.D.) 2007 Molecular epidemiology of pneumococcal carriage and invasive disease Karin Sjöström Molecular Epidemiology of Pneumococcal
More informationExtremely High Incidence of Macrolide and Trimethoprim- Sulfamethoxazole Resistance among Clinical Isolates of Streptococcus pneumoniae in Taiwan
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1999, p. 897 901 Vol. 37, No. 4 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Extremely High Incidence of Macrolide
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationBordetella pertussis Lipid A Glucosamine Modification Confers Resistance to Cationic
AAC Accepts, published online ahead of print on 27 May 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02590-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Bordetella
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationReceived 16 September 1999/Returned for modification 24 December 1999/Accepted 31 January 2000
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2000, p. 1575 1580 Vol. 38, No. 4 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. A Novel Multiresistant Streptococcus
More informationBacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B.
UvA-DARE (Digital Academic Repository) Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B. Link to publication Citation for published version (APA): Heckenberg,
More informationSupplemental Material for. Figure S1. Identification of TetR responsive promoters in F. novicida and E. coli.
Supplemental Material for Synthetic promoters functional in Francisella novicida and Escherichia coli Ralph L. McWhinnie and Francis E. Nano Department of Biochemistry and Microbiology, University of Victoria,
More informationThe Journal of Experimental Microbiology & Immunology+ Yasaman Jalalkamali, Niknaz Malekafzali, Raisa Shabbir, Tianna Sihota
Vol 4:1-10 The Journal of Experimental Microbiology & Immunology+ The RcsB-dependent Upregulation of rpra Contributes to the Intrinsic Antibiotic Resistance of Escherichia coli Exposed to Antibiotics Targeting
More informationTHE STRONGEST RESISTANCE OF Staphylococcus aureus TO ERYTHROMYCIN IS CAUSED BY DECREASING UPTAKE OF THE ANTIBIOTIC INTO THE CELLS
CELLULAR & MOLECULAR BIOLOGY LETTERS http://www.cmbl.org.pl Received: 06 February 2012 Volume 17 (2012) pp 633-645 Final form accepted: 07 September 2012 DOI: 10.2478/s11658-012-0034-3 Published online:
More informationStreptococcus pyogenes
Streptococcus pyogenes From Wikipedia, the free encyclopedia Streptococcus pyogenes S. pyogenes bacteria at 900x magnification. Scientific classification Kingdom: Eubacteria Phylum: Firmicutes Class: Cocci
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationCharacteristics of Streptococcus pseudopneumoniae Isolated from Purulent Sputum Samples
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2006, p. 923 927 Vol. 44, No. 3 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.3.923 927.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Characteristics
More informationby author ESCMID Online Lecture Library Steroids in acute bacterial meningitis
Steroids in acute bacterial meningitis Javier Garau, MD, PhD University of Barcelona Spain ESCMID Summer School, Porto, July 2009 Dexamethasone treatment in childhood bacterial meningitis in Malawi: a
More informationSerotype and genotype replacement among macrolide-resistant invasive. pneumococci in adults. Mechanisms of resistance and association with different
JCM Accepts, published online ahead of print on 10 February 2010 J. Clin. Microbiol. doi:10.1128/jcm.01868-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationBacterial Mechanisms of Pathogenicity. 2 nd Lecture
Bacterial Mechanisms of Pathogenicity 2 nd Lecture Preferred Portal of Entry Just because a pathogen enters your body it does not mean it s going to cause disease. pathogens - preferred portal of entry
More informationViral vaccines. Lec. 3 أ.د.فائزة عبد هللا مخلص
Lec. 3 أ.د.فائزة عبد هللا مخلص Viral vaccines 0bjectives 1-Define active immunity. 2-Describe the methods used for the preparation of attenuated live & killed virus vaccines. 3- Comparison of Characteristics
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationHaemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018
Haemophilus influenzae and its invisibility cloak Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018 Haemophilus influenzae Gram negative aerobic coccobacilli Pfeiffer s Bacillus-
More informationPotential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationSpecificity of Human Antibodies Reactive with Pneumococcal C Polysaccharide
INFECTION AND IMMUNITY, Apr. 2000, p. 2333 2337 Vol. 68, No. 4 0019-9567/00/$04.00 0 Specificity of Human Antibodies Reactive with Pneumococcal C Polysaccharide CARL E. FRASCH* AND NELYDIA F. CONCEPCION
More informationBurton's Microbiology for the Health Sciences
Burton's Microbiology for the Health Sciences Section VII. Pathogenesis and Host Defense Mechanisms Burton's Microbiology for the Health Sciences Chapter 14. Pathogenesis of Infectious Diseases 1 Chapter
More informationReport on susceptibility of Salmonella serotypes in Belgium Vicky Jasson
CODA-CERVA Report on susceptibility of Salmonella serotypes in Belgium 2014. Vicky Jasson Veterinary and Agrochemical Research Centre 1 Introduction Salmonella is one of the most important bacterial zoonotic
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More informationRifampin Resistance. Charlottesville, Virginia i0w organisms in Trypticase soy broth (BBL Microbiology
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1980, p. 658-662 0066-4804/80/04-0658/05$02.00/0 Vol. 17, No. 14 Treatment of Experimental Staphylococcal Infections: Effect of Rifampin Alone and in Combination
More informationNovel 12-Membered Ring Macrolides with Activity against. Erythromycin-resistant
VOL. 56 NO. 4, APR. 2003 THE JOURNAL OF ANTIBIOTICS pp. 392-398 Novel 12-Membered Ring Macrolides with Activity against Erythromycin-resistant Organisms Infectious Disease Research, Abbott Laboratories,
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationReceived 26 June 1995/Returned for modification 15 September 1995/Accepted 5 February 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1996, p. 941 946 Vol. 40, No. 4 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Amoxicillin Dose-Effect Relationship with Streptococcus
More informationHigh-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2003, p. 3179 3186 Vol. 47, No. 10 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.10.3179 3186.2003 Copyright 2003, American Society for Microbiology. All Rights
More informationThe Bacteriology of Bronchiectasis in Australian Indigenous children
The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies
More informationHigh-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia
High-Dose Levofloxacin for the Treatment of Community-Acquired Pneumonia Review Andrew F. Shorr, MD, MPH, FCCP Department of Medicine Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington,
More informationTitle. Author(s) Issue Date Right. Reserved.
NAOSITE: Nagasaki University's Ac Title Author(s) Rapid identification of penicillin simultaneous quantification of Stre sputum samples by use of a novel re Fukushima, Kazuko Y; Yanagihara, Ka Kazuyuki;
More informationMultidrug Resistant Pseudomonas aeruginosa. Presenter: Andrew Webb Block Lecturer: George Zhanel Date: 10 January 2019
Multidrug Resistant Pseudomonas aeruginosa Presenter: Andrew Webb Block Lecturer: George Zhanel Date: 10 January 2019 1 Pseudomonas aeruginosa Not a member of human microbiome Inhabitant of soil and moist
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationHigh dose amoxicillin for sinusitis
High dose amoxicillin for sinusitis Amoxil ( amoxicillin ) is a commonly used penicillin antibiotic. It is produced in tablets (500 mg 875 mg), capsules, chewable tablets and oral suspensions. 6-3-2018
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationDetection of the Efflux-Mediated Erythromycin Resistance Transposon in Streptococcus pneumoniae
Original Article Clinical Microbiology Ann Lab Med 2015;35:57-61 http://dx.doi.org/10.3343/alm.2015.35.1.57 ISSN 2234-3806 eissn 2234-3814 Detection of the Efflux-Mediated Erythromycin Resistance Transposon
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationVitamin D and the Human Antimicrobial Peptide LL-37 Enhance Group A Streptococcus Resistance to Killing by Human Cells
RESEARCH ARTICLE Vitamin D and the Human Antimicrobial Peptide LL-37 Enhance Group A Streptococcus Resistance to Killing by Human Cells John F. Love, a,b * Hien J. Tran-Winkler, a and Michael R. Wessels
More informationThe Importance of Appropriate Treatment of Chronic Bronchitis
...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,
More informationAntimicrobial Peptides in Defense and Inflammatory Skin Diseases
Antimicrobial Peptides in Defense and Inflammatory Skin Diseases Richard L. Gallo, M.D.,Ph.D. Professor of Medicine and Pediatrics, Chief, Division of Dermatology!The Problem Mycobacterium TB Pseudomonas
More informationStreptococcus pneumoniae: serotype diversity and epidemiology Dr Bambos Charalambous
Streptococcus pneumoniae: Serotype Diversity and Epidemiology 1 Senior Lecturer in Clinical Microbiology University College London, UK Overview Capsule, serotype and antigenicity Global serotype distribution:
More informationMolecular Characterization of Penicillin-Resistant Streptococcus pneumoniae Isolates from Bulgaria
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1999, p. 638 648 Vol. 37, No. 3 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Molecular Characterization of Penicillin-Resistant
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationORIGINAL ARTICLE. S. D. Putnam 1, G. C. Gray 2, D. J. Biedenbach 3 and R. N. Jones 3
ORIGINAL ARTICLE Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin S. D. Putnam 1,
More informationAnti-Microbial Drugs
Name: Date: Monday March 7 th 2011 Class: I "Pharmacology Anti-Microbial Drugs Lecture 5 د. حيدر الشكرجي Macrolides: Anti-Microbial Drugs Erythromycin was the 1 st of macrolides to find clinical application,
More information